Want to see CABA full AI Analyst Report?
CABA Stock Chart & Stats
$2.69
-$0.03(-1.10%)
At close: 4:00 PM EDT
$2.69
-$0.03(-1.10%)
Day’s Range― - ―
52-Week Range$1.26 - $4.23
Previous Close$2.74
Volume1.66M
Average Volume (3M)5.47M
Market Cap
$456.55M
Enterprise Value$211.16
Total Cash (Recent Filing)$116.64M
Total Debt (Recent Filing)$26.45M
Price to Earnings (P/E)―
Beta4.03
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding163,054,800
10 Day Avg. Volume2,844,121
30 Day Avg. Volume5,468,593
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.75Price Target Upside485.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Defined Pivotal Path And Expanding Registrational PlanA clear regulatory and development path across multiple autoimmune indications reduces program uncertainty and concentrates resources on registrational studies. Targeting systemic sclerosis and planned cohorts with timelines to topline readouts strengthens the probability of clinical milestones and eventual approval pathways, which supports durable franchise building and longer-term strategic planning.
Manufacturing Scalability Progress With AutomationDemonstrated equivalence between automated and manual manufacturing is a durable operational positive: it supports reproducible, scalable supply, reduces dependence on labor-intensive processes, and lowers future cost-of-goods risks. This progress materially improves commercial readiness and the feasibility of broad patient access if approvals are secured.
Material Capital Raise With Strategic Investor ParticipationThe $150M equity raise materially extends operating runway and reduces near-term financing pressure, enabling progression of pivotal studies and manufacturing scale-up. Participation by strategic and institutional investors, including Eli Lilly, provides validation, potential partnership optionality, and long-term support that enhances the company's ability to execute clinical and commercialization plans.
Bears Say
Pre-revenue With Accelerating Negative Cash FlowSustained zero product revenue coupled with rapidly increasing operating cash outflows creates persistent financing dependence. Ongoing negative free cash flow erodes capital reserves and forces repeated capital raises or partnerships, which constrains strategic optionality and raises execution risk if clinical timelines slip or costs rise, affecting long-term viability without successful approvals.
Increased Structural Dilution Risk From Share Authorization IncreaseDoubling authorized shares materially increases the company's ability to issue equity for funding or strategic deals. For a pre-revenue biotech with ongoing burn, this structural change raises the probability of meaningful dilution over the coming years, weakening existing ownership stakes and potentially reducing incentives for long-term shareholders absent clear near-term value inflection points.
Material Depletion Of Equity And Assets Over Recent YearsLarge declines in shareholders' equity and total assets highlight that cash burn is eroding the balance sheet, reducing financial resilience. A shrinking capital base limits ability to absorb trial delays or adverse data, increases reliance on external financing at potentially unfavorable terms, and undermines balance-sheet flexibility needed for durable R&D execution.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio, Inc.’s price range in the past 12 months?
Cabaletta Bio, Inc. lowest stock price was $1.26 and its highest was $4.23 in the past 12 months.
What is Cabaletta Bio, Inc.’s market cap?
Cabaletta Bio, Inc.’s market cap is $456.55M.
When is Cabaletta Bio, Inc.’s upcoming earnings report date?
Cabaletta Bio, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 85 days.
How were Cabaletta Bio, Inc.’s earnings last quarter?
Currently, no data Available
Is Cabaletta Bio, Inc. overvalued?
According to Wall Street analysts Cabaletta Bio, Inc.’s price is currently Undervalued.
Does Cabaletta Bio, Inc. pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
What is Cabaletta Bio, Inc.’s EPS estimate?
Cabaletta Bio, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cabaletta Bio, Inc. have?
Cabaletta Bio, Inc. has 163,054,800 shares outstanding.
What happened to Cabaletta Bio, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cabaletta Bio, Inc.?
Currently, no hedge funds are holding shares in CABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cabaletta Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (485.50% Upside)
$15.75 (485.50% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 61.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.29%
Trailing 12-Months
Company Description
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. (CABA) is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. The company’s core pipeline centers on chimeric autoantibody receptor T (CAAR-T) programs designed to selectively target and eliminate autoreactive B cells, with lead efforts in diseases such as pemphigus vulgaris and other B-cell–mediated autoimmune conditions. Cabaletta operates in the biotechnology/pharmaceutical R&D sector and does not market approved products as of its clinical-stage profile.
CABA Stock 12 Month Forecast
Average Price Target
$15.75
▲(485.50% Upside)
Technical Analysis
Tonix Pharma
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Entrada Therapeutics Inc
―
Ownership Overview
1.04% Insiders
9.86% Mutual Funds
13.61% Other Institutional Investors
61.72% Public Companies and
Individual Investors